Upadacitinib 30 mg for the optimal management of moderate-to-severe atopic dermatitis: a 52-week single-center real-world study

被引：1
|
作者：
Gargiulo, Luigi [1 ,2 ]
Ibba, Luciano [1 ,2 ]
Bianco, Matteo [1 ,2 ]
Di Giulio, Sara [1 ,2 ]
Alfano, Alfano [1 ,2 ]
Ingurgio, Ruggero Cascio [1 ,2 ]
Facheris, Paola [1 ]
Perugini, Chiara [1 ]
Valenti, Mario [1 ,2 ]
Costanzo, Antonio [1 ,2 ]
Narcisi, Alessandra [1 ]
机构：
[1] IRCCS Humanitas Res Hosp, Dermatol Unit, Rozzano, Italy
[2] Humanitas Univ, Dept Biomed Sci, Pieve Emanuele, Italy
来源：
JOURNAL OF DERMATOLOGICAL TREATMENT | 2024年 / 35卷 / 01期
关键词：
DOUBLE-BLIND; ADOLESCENTS; PLACEBO; ADULTS; SAFETY;
D O I：
10.1080/09546634.2024.2375102
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Treatment optimization with secukinumab 150 mg for moderate-to-severe psoriasis in clinical practice: a single-center open-label 52-week study
    Munoz-Santos, Carlos
    Sola-Ortigosa, Joaquin
    Guilabert, Antonio
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2018, 57 (05) : 615 - 617
  • [22] Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study
    Hagino, Teppei
    Saeki, Hidehisa
    Fujimoto, Eita
    Kanda, Naoko
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2024, 35 (01)
  • [23] Dupilumab for moderate-severe atopic dermatitis: a real-world, single-center retrospective study of 122 patients in the United States
    Emmerich, Veronica K.
    Williams, Josiah A.
    Hrin, Matthew L.
    Feldman, Steven R.
    Strowd, Lindsay C.
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2024, 63 (04) : 524 - 525
  • [24] Real-World Effectiveness and Safety of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis in Adult Patients: A 52-Week Multicenter Retrospective Study
    Yeung, Jensen
    Sood, Siddhartha
    JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2024,
  • [25] Cost per responder of upadacitinib 30 mg and dupilumab 300 mg in patients with moderate-to-severe atopic dermatitis in italy
    Stingeni, Luca
    Ravasio, Roberto
    Palladino, Chiara
    Di Fino, Sara
    Levi, Anna
    Ronci, Gianluca
    Gisondi, Paolo
    GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2025, 12 : 70 - 79
  • [26] Dupilumab treatment in adult patients with moderate to severe atopic dermatitis: A real-world single-center experience from Turkey
    Salman, Andac
    Aktas, Meryem
    Ozkurkcu, Esra
    Sarac, Gonca
    Taskapan, Oktay
    Ergun, Tulin
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB144 - AB144
  • [27] The efficacy and safety of upadacitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan
    Hagino, Teppei
    Saeki, Hidehisa
    Kanda, Naoko
    JOURNAL OF DERMATOLOGY, 2022, 49 (11): : 1158 - 1167
  • [28] Upadacitinib effectiveness in moderate-to-severe atopic dermatitis: A real-life multicentre and retrospective study
    Ramos, F. Javier Melgosa
    Gonzalez-Delgado, Victor
    Motilla, Jose Maria Sanchez
    Marta, Galarreta Pascual
    Mateu Puchades, Almudena
    Sergio, Santos Alarcon
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 (04) : e361 - e364
  • [29] QUALITY OF LIFE AND TREATMENT SATISFACTION WITH TILDRAKIZUMAB IN MODERATE-TO-SEVERE PSORIASIS PATIENTS: 52-WEEK INTERIM DATA OF THE REAL-WORLD POSITIVE STUDY
    Augustin, Matthias
    Sommer, Raquel
    Reguiai, Ziad
    Gerdes, Sascha
    Dauden, Esteban
    Weger, Wolfgang
    Maul, Julia-Tatjana
    Laws, Philip
    Naldi, Luigi
    Ghislain, Pierre-Dominique
    de Jong, Elke
    Mburu, Sicily
    Koscielny, Volker
    Massana, Eric
    Kasujee, Ismail
    Mrowietz, Ulrich
    ACTA DERMATO-VENEREOLOGICA, 2024, 104
  • [30] Effectiveness of long-term bimekizumab treatment and predictive factors for responders in moderate-to-severe psoriasis: A 52-week real-world study
    Hagino, Teppei
    Saeki, Hidehisa
    Fujimoto, Eita
    Kanda, Naoko
    JOURNAL OF DERMATOLOGY, 2025, 52 (02): : 317 - 328
12345